全文获取类型
收费全文 | 38597篇 |
免费 | 3929篇 |
国内免费 | 2717篇 |
专业分类
耳鼻咽喉 | 297篇 |
儿科学 | 553篇 |
妇产科学 | 415篇 |
基础医学 | 3302篇 |
口腔科学 | 597篇 |
临床医学 | 5335篇 |
内科学 | 4829篇 |
皮肤病学 | 281篇 |
神经病学 | 1438篇 |
特种医学 | 1271篇 |
外国民族医学 | 13篇 |
外科学 | 3155篇 |
综合类 | 8660篇 |
现状与发展 | 25篇 |
一般理论 | 1篇 |
预防医学 | 3580篇 |
眼科学 | 704篇 |
药学 | 4991篇 |
53篇 | |
中国医学 | 3057篇 |
肿瘤学 | 2686篇 |
出版年
2024年 | 173篇 |
2023年 | 556篇 |
2022年 | 1397篇 |
2021年 | 1759篇 |
2020年 | 1429篇 |
2019年 | 1092篇 |
2018年 | 1092篇 |
2017年 | 1223篇 |
2016年 | 1043篇 |
2015年 | 1726篇 |
2014年 | 2218篇 |
2013年 | 2324篇 |
2012年 | 3456篇 |
2011年 | 3460篇 |
2010年 | 2595篇 |
2009年 | 2142篇 |
2008年 | 2435篇 |
2007年 | 2483篇 |
2006年 | 2285篇 |
2005年 | 2074篇 |
2004年 | 1506篇 |
2003年 | 1507篇 |
2002年 | 1161篇 |
2001年 | 880篇 |
2000年 | 763篇 |
1999年 | 569篇 |
1998年 | 336篇 |
1997年 | 317篇 |
1996年 | 217篇 |
1995年 | 224篇 |
1994年 | 185篇 |
1993年 | 98篇 |
1992年 | 88篇 |
1991年 | 73篇 |
1990年 | 90篇 |
1989年 | 55篇 |
1988年 | 46篇 |
1987年 | 40篇 |
1986年 | 57篇 |
1985年 | 27篇 |
1984年 | 8篇 |
1983年 | 12篇 |
1982年 | 3篇 |
1981年 | 7篇 |
1980年 | 5篇 |
1979年 | 4篇 |
1973年 | 1篇 |
1970年 | 1篇 |
1963年 | 1篇 |
排序方式: 共有10000条查询结果,搜索用时 21 毫秒
2.
3.
Tianying Yang Jiawei Li Yichen Jia Chunchen Yang Ruirui Sang Tongyu Zhu Ming Xu Ruiming Rong Cheng Yang 《Translational andrology and urology》2021,10(1):204
BackgroundIn the field of transplantation, inducing immune tolerance in recipients is of great importance. Blocking co-stimulatory molecule using anti-CD28 antibody could induce tolerance in a rat kidney transplantation model. Myeloid-derived suppressor cells (MDSCs) reveals strong immune suppressive abilities in kidney transplantation. Here we analyzed key genes of MDSCs leading to transplant tolerance in this model.MethodsMicroarray data of rat gene expression profiles under accession number in the Gene Expression Omnibus (GEO) database were analyzed. Running the LIMMA package in R language, the differentially expressed genes (DEGs) were found. Enrichment analysis of the DEGs was conducted in the Database for Annotation, Visualization and Integrated Discovery (DAVID) database to explore gene ontology (GO) annotation and their Kyoto Encyclopedia of Genes and Genomes (KEGG) pathways. Their protein-protein interactions (PPIs) were provided by STRING database and was visualized in Cytoscape. Hub genes were carried out by CytoHubba.ResultsThree hundred and thirty-eight DEGs were exported, including 27 upregulated and 311 downregulated genes. The functions and KEGG pathways of the DEGs were assessed and the PPI network was constructed based on the string interactions of the DEGs. The network was visualized in Cytoscape; the entire PPI network consisted of 192 nodes and 469 edges. Zap70, Cdc42, Stat1, Stat4, Ccl5 and Cxcr3 were among the hub genes.ConclusionsThese key genes, corresponding proteins and their functions may provide valuable background for both basic and clinical research and could be the direction of future studies in immune tolerance, especially those examining immunocyte-induced tolerance. GSE28545相似文献
4.
人类微生物群是由寄生在人体上皮屏障的细菌和其他微生物组成的,其中大部分位于肠道内,与宿主之间形成共生的关系。机体肠道微生物的组成虽然受到年龄、饮食、生活方式等因素的影响,但在正常生理情况下是相对稳定的。近年来,肠道菌群与恶性肿瘤的关系越来越受到重视。肠道菌群不但能够维持局部稳态,还能调节机体代谢、炎症和免疫等生理过程。有研究表明,微生物群,特别是肠道菌群能够显著调节机体对癌症治疗的反应性以及机体对毒副反应的敏感性。检查肠道菌群中各菌种之间的比例可作为筛查恶性肿瘤的新方法。本文将综述微生物群具有影响肿瘤的发生发展、抗肿瘤治疗疗效以及药物不良反应的证据,以及其中所涉及的微生物种类,从而为恶性肿瘤精准治疗提供证据。 相似文献
5.
6.
目的 探讨糖尿病前期的中医证型及证素分布特点。方法 检索中国知网、万方及维普三大数据库中收录的自建库以来有关糖尿病前期证型的临床研究文献,对中医证型进行规范整理,建立数据库,提取证素,运用数据挖掘技术中的关联分析、聚类分析探究证素分布规律。结果 共纳入10篇文献,总有效病例1620例,证型经规范处理后整理为18个,主要证型为脾虚痰湿证。共提取证素13个,主要病位证素为脾,主要病性证素为气虚、湿和痰,关联分析显示脾—湿支持度和置信度最高,聚类分析结果可得到3个聚类组。结论 糖尿病前期病位在脾,气虚、脾、痰、湿是常见证素,临床诊治糖尿病前期应注重从脾论治,需辨证施治。 相似文献
7.
Katie Mycock Lin Zhan Gavin Taylor-Stokes Gary Milligan Debanjali Mitra 《Current oncology (Toronto, Ont.)》2021,28(1):678
Background: Palbociclib is a selective cyclin-dependent kinase (CDK) 4/6 inhibitor used in combination with aromatase inhibitors or fulvestrant for patients with hormone receptor-positive (HR+) human epidermal growth factor receptor 2 (HER2)-negative advanced/metastatic breast cancer (ABC/MBC). Palbociclib was the first CDK 4/6 inhibitor approved for HR+/HER2− ABC/MBC treatment in Canada in combination with letrozole (P+L) as an initial endocrine-based therapy (approved March 2016), or with fulvestrant (P+F) following disease progression after prior endocrine therapy (approved May 2017). The Ibrance Real World Insights (IRIS) study () collected real-world outcomes data for palbociclib-treated patients in several countries, including Canada. Methods: This retrospective chart review included women with HR+/HER2− ABC/MBC receiving P+L or P+F in Canada. Physicians reviewed medical records for up to 14 patients, abstracting demographic and clinical characteristics, treatment patterns, and clinical outcomes. Progression-free rates (PFRs) and survival rates (SRs) at 6, 12, 18, and 24 months were estimated via Kaplan–Meier analysis. Results: Thirty-three physicians examined medical records for 247 patients (P+L, n = 214; P+F, n = 33). Median follow-up was 8.8 months for P+L and 7.0 months for P+F. Most patients were initiated on palbociclib 125 mg/d (P+L, 90.2%; P+F, 84.8%). Doses were reduced in 16.6% of P+L and 14.3% of P+F patients initiating palbociclib at 125 mg/d. The PFR for P+L was 90.3% at 12 months and 78.2% at 18 months; corresponding SRs were 95.6% and 93.0%. For P+F, 6-month PFR was 91.0%; 12-month SR was 100.0%. Conclusions: Dose reduction rates were low and PFR and SR were high in this Canadian real-world assessment of P+L and P+F treatments, suggesting that palbociclib combinations are well tolerated and effective. NCT03159195相似文献
8.
9.
10.